| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | Ralinepag, APD811, Placebo | United Therapeutics | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | 12/25 | 12/25 | | |
NCT04482595: BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients |
|
|
| Active, not recruiting | 2 | 50 | US | BIO 300 Oral Suspension, Placebo | Humanetics Corporation, NYU Langone Health, National Institute of Allergy and Infectious Diseases (NIAID) | COVID-19, Long COVID, Pulmonary Fibrosis, Post-acute Respiratory Complications of COVID-19 | 07/24 | 04/25 | | |
